Ultragenyx bags first gene therapy approval as previously rejected Sanfilippo asset awaits decision
RegulatoryUX111Positive
AI Analysis
Summary
Ultragenyx received accelerated approval for a gene therapy treating glycogen storage disease, raising analyst expectations for approval of UX111, its previously rejected Sanfilippo asset, with an FDA decision expected by mid-September 2026.
Outcome Details
FDA previously rejected UX111; second review pending decision by mid-September 2026
Importance:8/10
Sentiment:
0.60
gene therapyFDA approvalSanfilippo syndromeglycogen storage diseaseregulatory decision
Related Companies
Read the original article
Published by BioSpace on August 20, 2026 12:08 PM